Each month the AJG Co-Editors-in-Chief, Dr. Jasmohan Bajaj and Dr. Millie Long, interview the author of a key article highlighting important clinical science for practicing gastrointestinal specialists.
You can subscribe and download episodes via:
January 2021
Dr. Mark Pimentel
Mark Pimentel, MD, FACG, discusses the newly published ACG Guideline for Management of Irritable Bowel Syndrome. (27:59)
February 2019
Dr. Mark Pimentel
Mark Pimentel, MD, FACG, discusses non-pharmaceutical management approaches for IBS, including gluten-free diet, dairy-free diet, low FODMAP diet, and fiber. (21:55)
January 2014
Dr. Robin C. Spiller
Robin C. Spiller, MD, FRCP, co-author of new research on the effect of FODMAPs such as fructose and fructans on irritable bowel syndrome (IBS) symptoms published in the January 2014 issue of AJG, talks with AJG Co-Editor Dr. William D. Chey about the dietary substances included in the FODMAP classification, the MRI imaging techniques used to measure FODMAP impact on colonic distention and gas production in this study, and how clinicians might consider FODMAPs along with gluten and lactose when recommending dietary interventions for IBS patients. (21:53)
November 2012
Dr. William D. Chey and Dr. Satish Rao
Dr. Paul Moayyedi talks with William D. Chey, MD, FACG and Satish Rao, MD, PhD, FACG about two randomized controlled trials on linaclotide in irritable bowel syndrome (IBS) published in the December issue of The American Journal of Gastroenterology. The phase 3 trials report that this new therapy significantly reduces constipation and abdominal pain associated with some kinds of IBS. (35:31)
October 2012
Dr. Alexander C. Ford and Dr. Eamonn M. M. Quigley
Paul Moayyedi, MD, FACG, talks with Alexander C. Ford, MD, and Eamonn M. M. Quigley, MD, FACG, about the findings from the first systematic review of the literature of irritable bowel syndrome symptoms in inflammatory bowel disease. In the review, Dr. Ford and his co-investigator Stephen J. Halpin, MD, demonstrated that prevalence of symptoms compatible with IBS in patients with IBD is as high as 40%. This article and Dr. Quigley’s editorial “Irritable Bowel Symptoms in IBD: Diagnostic Uncertainty Meets Pathological Reality” were published in the October issue of the AJG. (23:08)